Изчислете точни обеми за реконституция, инсулинови единици и дози на флакон за всеки пептид.
GHRP-2 (Growth Hormone Releasing Peptide-2, also known as pralmorelin or KP-102) is a synthetic hexapeptide composed of six amino acids. It belongs to the class of growth hormone secretagogues and acts as a ghrelin mimetic, prompting the body to release its own growth hormone (GH). Unlike the direct administration of recombinant growth hormone, GHRP-2 does not introduce GH from an external source. Instead, it stimulates the pituitary gland to amplify its own pulsatile GH bursts, which means the natural feedback mechanisms of the GH axis remain largely intact.
GHRP-2 was developed during the 1980s and 1990s as part of the search for small-molecule GH secretagogues, making it one of the longest-studied peptides in its class. In research literature, GHRP-2 is frequently positioned between GHRP-6 and ipamorelin. It is more potent than GHRP-6 in terms of raw GH release, yet it tends to produce less appetite stimulation. At the same time, it is considered less selective than ipamorelin, since it can influence prolactin and cortisol to a modest degree.
GHRP-2 is used and studied strictly for research purposes. It binds to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus — the same receptor targeted by the body's own hormone ghrelin. Because of its short half-life of roughly two hours, most research protocols administer GHRP-2 several times per day to generate repeated GH pulses.
GHRP-2 exerts its effects by activating the ghrelin receptor and modulating the downstream GH axis. The principal mechanisms can be summarized as follows:
GHRP-2 does not typically require a slow titration ramp. Most protocols begin directly within the moderate dose range and split the daily amount across several individual injections to take advantage of the pulsatile nature of the GH axis.
A commonly cited reference point is the so-called saturating dose of approximately 1 mcg per kilogram of body weight. In research, doses above this threshold add little additional GH release while increasing the risk of ancillary-axis effects such as elevated cortisol or prolactin. Most protocols therefore remain in the range of 100 mcg per injection.
The most common vial size for GHRP-2 is 5 mg. Adding 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL (2,500 mcg/mL).
The volumes to draw for GHRP-2 are very small. If the volume to withdraw falls below 0.05 mL, a larger reconstitution volume can improve measurement accuracy. If the 5 mg vial is reconstituted with 5 mL of BAC water instead of 2 mL, the concentration becomes 1 mg/mL, and a 100 mcg dose then corresponds to 0.10 mL, or 10 units. At a typical daily amount of 300 mcg (3 × 100 mcg), a 5 mg vial lasts roughly 16 days on paper. Use the GHRP-2 calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.
GHRP-2 is supplied as a lyophilized (freeze-dried) powder in sealed vials. It must be reconstituted with bacteriostatic water (BAC water) before use. Sterile water for injection should not be used for multi-dose vials — BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and meaningfully extends the usable window of the reconstituted solution.
If the solution appears cloudy, discolored, or contains visible particulate matter, the vial should be discarded and not used.
GHRP-2 has been studied for several decades and is regarded as comparatively well tolerated at research doses. Because it stimulates GH release through the body's own pituitary gland, physiological feedback mechanisms remain largely intact. Nevertheless, GHRP-2 is not an approved drug, and comprehensive long-term human data is lacking.
No serious adverse events have been attributed to GHRP-2 in the published literature at standard research doses. However, given the absence of large-scale long-term human trials, caution is warranted, and consultation with a qualified healthcare professional is strongly recommended.
The most potent and best-documented combination for GHRP-2 is pairing it with a GHRH analog, most prominently CJC-1295 without DAC (also known as Mod GRF 1-29). The two peptides act on the same somatotroph cell population in the pituitary, but through different receptors:
A typical research protocol combines 100 mcg of GHRP-2 with 100 mcg of CJC-1295 without DAC per injection, 2 to 3 times daily. Because CJC-1295 without DAC has a half-life similar to that of GHRP-2, both can be administered comfortably within the same time window.
All three peptides are ghrelin mimetics, but they differ in profile. Ipamorelin is considered the most selective GHRP, with the least effect on cortisol and prolactin, and is therefore often preferred when ancillary-axis effects should be minimized. GHRP-6 produces the strongest appetite stimulation and is used in research specifically when a hunger signal is desired. GHRP-2 occupies a middle position: a stronger GH release than GHRP-6 with a moderate appetite effect. Hexarelin is the most potent member of the class, but it is also the most prone to receptor desensitization.
GHRP-2 should ideally be administered on an empty stomach, as high blood glucose and fatty-acid levels can blunt the GH response. A gap of roughly 20 to 30 minutes between the injection and the next meal is common in many protocols. When several peptides are combined, each should be reconstituted separately. Administering them in separate syringes eliminates dosing errors, even though adjacent injection sites can be used.
Both are ghrelin-mimetic secretagogues, but GHRP-2 is more potent in terms of raw GH release and triggers noticeably weaker appetite stimulation. GHRP-6 produces a pronounced sensation of hunger, which can be desirable in research but is also inconvenient when that effect is not wanted. For a comparable GH response, slightly lower doses of GHRP-2 are therefore typically used.
High blood levels of insulin and fatty acids dampen the pituitary's GH response. Administering on an empty stomach — roughly two hours after the last meal and at least 20 to 30 minutes before the next — allows the strongest GH burst in research. The carbohydrate and fat content of a meal shortly before the injection can in particular weaken the effect.
Because of its short half-life of around two hours, most research protocols use 2 to 3 administrations per day. Common timings are in the morning on an empty stomach, before training, and before sleep, since the largest natural GH pulse already occurs during the early deep-sleep phase.
At moderate doses, GHRP-2 has only a small effect on cortisol and prolactin. As the dose rises, however, this ancillary-axis effect increases. For this reason, most research protocols stay around 100 mcg per injection and avoid significantly exceeding the saturating dose, since beyond it there is little additional GH gain but more side effects to expect.
Yes — combining a GHRP with a GHRH analog such as CJC-1295 without DAC is the most frequently studied stack variant. Because the two act through different receptors, they amplify GH release synergistically. In typical protocols, both peptides are administered at the same time and within the same window, but reconstituted from separate vials.
In research, cyclical protocols of roughly 8 to 12 weeks followed by breaks are common. Breaks are scheduled as a precaution to guard against possible desensitization of the GHS-R1a receptors, even though robust long-term human data is limited. The dose is generally held constant throughout a cycle.
GHRP-2 is on the World Anti-Doping Agency (WADA) prohibited list and is banned as a growth hormone secretagogue both in and out of competition. Specialized analytical methods can detect GHRP-2 and its metabolites. Athletes subject to WADA-compliant testing should always verify the applicable anti-doping rules in advance.
GHRP-2 does not suppress the GH axis in the classical sense, because it stimulates the pituitary rather than supplying hormones from outside. Natural GH production fundamentally remains intact. In theory, very long and high-dose use can reduce receptor sensitivity, which is why breaks between cycles are recommended. Unlike steroid-based interventions, no dedicated post-cycle therapy is required.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. GHRP-2 is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. The legal status of peptides varies by region, and compliance with local regulations is your responsibility. BergdorfBio assumes no liability for the use or misuse of the information presented here.